D70.1 – Agranulocytosis secondary to cancer chemotherapy

ICD-10-CM 2027 diagnosis code · Other disorders of blood and blood-forming organs

Billable code

ICD-10-CM code D70.1
Code
D70.1 (claims format: D701)
Description
Agranulocytosis secondary to cancer chemotherapy
Billable
Yes – valid for HIPAA-covered transactions
Valid for
Dates of service October 1, 2026 – September 30, 2027 (FY2027)
Chapter
3. Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Block
D70-D77 Other disorders of blood and blood-forming organs
Parent codes
D70

Notes for D70.1

Use additional code:
  • code for adverse effect, if applicable, to identify drug (T45.1X5)
Code also:
  • underlying neoplasm

Notes inherited from parent codes

Instructional notes at a category or block level apply to every code below it.

D70 – Neutropenia

Includes:
  • agranulocytosis
  • decreased absolute neurophile count (ANC)
Excludes1 (not coded here):
  • neutropenic splenomegaly (D73.81)
  • transient neonatal neutropenia (P61.5)
Use additional code:
  • code for any associated:
  • fever (R50.81)
Code also:

Index terms for D70.1

Entries in the ICD-10-CM alphabetic index that lead to this code:

Related codes in D70

Frequently asked questions

What is ICD-10 code D70.1?

D70.1 is the ICD-10-CM code for agranulocytosis secondary to cancer chemotherapy, in the block D70-D77 (Other disorders of blood and blood-forming organs).

Is D70.1 a billable code?

Yes. D70.1 is a billable/specific code that can be used to indicate a diagnosis for reimbursement purposes.

What category does D70.1 belong to?

It belongs to category D70 – Neutropenia.

Source: CDC/NCHS ICD-10-CM FY2027 code files, tabular list and index. Reference only – code assignment must follow the official ICD-10-CM guidelines and documentation in the medical record.